Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has received a consensus rating of “Buy” from the eight analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $69.5714.

MNPR has been the subject of several research reports. Oppenheimer initiated coverage on shares of Monopar Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $77.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $74.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Raymond James Financial initiated coverage on Monopar Therapeutics in a research report on Tuesday. They issued a “strong-buy” rating and a $80.00 target price for the company. Finally, Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Insider Buying and Selling

In related news, CEO Chandler Robinson sold 16,800 shares of the firm’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the transaction, the director directly owned 11,486 shares of the company’s stock, valued at approximately $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 over the last ninety days. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey bought a new position in Monopar Therapeutics in the second quarter worth $34,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics during the first quarter worth $44,000. JPMorgan Chase & Co. raised its stake in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics during the second quarter worth $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics during the second quarter worth $104,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $44.21 on Friday. The company has a market capitalization of $272.78 million, a price-to-earnings ratio of -13.28 and a beta of 1.20. Monopar Therapeutics has a one year low of $2.29 and a one year high of $54.30. The company’s fifty day moving average price is $38.33 and its two-hundred day moving average price is $36.65.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12. As a group, sell-side analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.